However, there are ccRCC tumors that are resistant to HIF-2α antagonists in both VHL wild-type (SLR21) ccRCC cell lines and patient-derived xenograft tumors with low level of HIF-2α [13,14]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.